These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32005243)

  • 1. Genomic profiles and transcriptomic microenvironments in 2 patients with synchronous lung adenocarcinoma and lung squamous cell carcinoma: a case report.
    Wu L; Kang P; Tao S; Zhao Z; Chen L; Xiao Y; Tan Q
    BMC Med Genomics; 2020 Jan; 13(1):15. PubMed ID: 32005243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
    Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N
    J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
    Cheng W; Xu B; Zhang H; Fang S
    Thorac Cancer; 2021 Sep; 12(18):2458-2467. PubMed ID: 34328274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
    Kim A; Lim SM; Kim JH; Seo JS
    Front Immunol; 2021; 12():598671. PubMed ID: 33717076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
    Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
    J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for common clonal origin of multifocal lung cancers.
    Wang X; Wang M; MacLennan GT; Abdul-Karim FW; Eble JN; Jones TD; Olobatuyi F; Eisenberg R; Cummings OW; Zhang S; Lopez-Beltran A; Montironi R; Zheng S; Lin H; Davidson DD; Cheng L
    J Natl Cancer Inst; 2009 Apr; 101(8):560-70. PubMed ID: 19351924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
    Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
    Fukuda H; Arai K; Mizuno H; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Maruyama T; Kuwabara K; Nishizawa T; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K
    Cancer Sci; 2024 Jun; 115(6):1763-1777. PubMed ID: 38527308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
    Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment.
    Cai MC; Zhao X; Cao M; Ma P; Chen M; Wu J; Jia C; He C; Fu Y; Tan L; Xue X; Yu Z; Zhuang G
    J Pathol; 2020 Jun; 251(2):147-159. PubMed ID: 32222046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
    Qu Y; Cheng B; Shao N; Jia Y; Song Q; Tan B; Wang J
    Aging (Albany NY); 2020 Mar; 12(6):4757-4777. PubMed ID: 32209727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
    Isaeva OI; Sharonov GV; Serebrovskaya EO; Turchaninova MA; Zaretsky AR; Shugay M; Chudakov DM
    J Immunother Cancer; 2019 Oct; 7(1):279. PubMed ID: 31665076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
    J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report.
    Nishimura R; Yoshida T; Torasawa M; Kashihara T; Ohe Y
    Thorac Cancer; 2023 Jan; 14(2):206-209. PubMed ID: 36453575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response.
    Lucchetta M; da Piedade I; Mounir M; Vabistsevits M; Terkelsen T; Papaleo E
    BMC Cancer; 2019 Aug; 19(1):824. PubMed ID: 31429720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.